Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The following is a summary of "Long-term weight change patterns in American adulthood in relation to gallstones: evidence from NHANES," published in the April 2025 issue of the BMC Gastroenterology by ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. View on euronews ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing. Obesity treatments have become one of the more promising ...

Before going over this late-stage trial, plus any catalysts to be released from this program, it is first important to go over what this disorder is. Acquired Hypothalamic obesity is a rare ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Danish biopharma powerhouse Novo Nordisk is taking ...

Danuglipron: According to the company's latest statement, one patient experienced a potential liver injury that may have been ...

April 7 (Reuters) - Rhythm Pharmaceuticals (RYTM.O), opens new tab said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity ... goal of a late-stage trial.

Josh Shapiro’s residence being treated at hospital, police say A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of ...